drugset / Trial / NCT00002742

Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer

NCT00002742

Phase 3 Completed Aronex Pharmaceuticals
RandomizedSupportive care

Summary

RATIONALE: Antifungal therapy with liposomal nystatin may reduce fever and neutropenia in patients undergoing treatment for hematologic cancer. It is not yet known whether liposomal nystatin is more effective than standard amphotericin B in treating patients with fever and neutropenia who are receiving chemotherapy for hematologic cancer or bone marrow transplantation for leukemia. PURPOSE: Randomized phase III trial to study the effectiveness of liposomal nystatin compared with standard amphotericin B to treat fever and neutropenia in patients receiving chemotherapy for hematologic cancer or bone marrow transplantation for leukemia.

Timeline

Start
1996-01
Primary completion
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Amphotericin B Unknown
Subject Nystatin Unknown